Given that JQ1 treatment can augment both drug penetration and CD8+ T cell infiltration into PDAC tissues, we evaluated the immunotherapy efficacy of IL12 at a lower dose of 250 μg k−1g in combination with JQ1 in the immunocompetent orthotopic pancreatic cancer mouse model. The gene discussed is CD8A; the disease is familial pancreatic carcinoma.